These genetic analysis strategies of the CYP21A2 gene with NGS technology represent a promising tool for the future, opening the window to identify new variants while improving the diagnosis of CYP21A2 deficiency and establishing a more reliable estimate of mutation frequencies. This evidence concerns the gene CYP21A2 and hyperinsulinemic hypoglycemia, familial, 4.